- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
MYGN Market Currents
more »
-
Monday 12:11 PM Myriad Genetics (MYGN +3.8%) gains on an upgrade to Outperform at Leerink Swann, saying believes concerns over the company's reimbursement risk and intellectual property are overdone and that the drug developers product lines are continuing to grow. The firm also raised its price target range to $30 - $31 from $27 - $30.
Comment![Healthcare, On the Move]
MYGN in Focus
more »
MYGN Related Articles
more »
MYGN News
more »
-
at MarketWatch.com (Jan 31, 2012)
-
at MarketWatch.com (Nov 1, 2011)
-
at MarketWatch.com (Sep 29, 2011)
-
at CNBC.com (Jun 15, 2011)
-
at CNBC.com (Dec 30, 2010)
MYGN Press Releases and Filings
more »
-
GlobeNewswire (Tue, 4:15PM)
-
GlobeNewswire (May 16, 2012)
-
GlobeNewswire (May 2, 2012)
-
GlobeNewswire (May 1, 2012)
-
GlobeNewswire (Apr 10, 2012)
MYGN Latest Transcript
more »
MYGN Cramer
more »
-
Thu, Jun 11, 2009
-
Thu, Apr 2, 2009
MYGN Instablog posts
more »
MYGN vs. ETF Alternatives
Company Description
Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel molecular diagnostic products. We believe that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. By understanding the genetic basis of disease, we... More
